UCBJF:OTCMKTS
UCB
240,24 USD
arrow_upward
+1,82%(+4,30) 1D
15. lis, 12:20:58 GMT -4 · USD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za UCBJF...
Otvori
240,24 USD
Najviša
240,24 USD
Najniža
240,24 USD
Trž. kap.
40,07 mlr.
Prosj. kol.
139,00
Količina
10,00
52-tjed. najviša
345,39 USD
52-tjed. najniža
219,60 USD
Beta
0,58
Dionice u optjecaju
194,51 mil.
Broj djelatnika
9 tis.
Otvori
240,24 USD
Najviša
240,24 USD
Najniža
240,24 USD
Trž. kap.
40,07 mlr.
Prosj. kol.
139,00
Količina
10,00
52-tjed. najviša
345,39 USD
52-tjed. najniža
219,60 USD
Beta
0,58
Dionice u optjecaju
194,51 mil.
Broj djelatnika
9 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
ad-hoc-news.de
·
prije 10 sati
UCB dedicates Georgia campus as UCB stock sits 29.15 percent below its high
ad-hoc-news.de
·
prije 1 dan
UCB dedicates Georgia site. UCB stock sits 30.78 percent below its high
Profil
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
UCB – informacije
Glavni izvršni direktorJean-Christophe Tellier
Zaposlenici9 tis.
Osnovano18. sij 1928.
Sjedište-
Sektor-
Web-lokacijaucb.com